Drug Profile


Alternative Names: VT-122

Latest Information Update: 06 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vicus Therapeutics LLC
  • Developer Vicus Therapeutics
  • Class Indoleacetic acids; Naphthalenes; Nonsteroidal anti-inflammatories; Propanolamines
  • Mechanism of Action Beta-adrenergic receptor antagonists; Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Liver cancer; Prostate cancer
  • Phase I Lung cancer; Solid tumours
  • No development reported Cachexia; Pancreatic cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 06 Oct 2016 Clinical development is ongoing for Pancreatic cancer (Combination therapy, Metastatic disease) in USA (Vicus Therapeutics pipeline, October 2016)
  • 16 Jul 2016 No recent reports of development identified for clinical development in Pancreatic-cancer(Combination therapy, Metastatic disease) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top